抗白细胞介素-13疫苗治疗哮喘的研究进展

Progress in research on anti-interleukin-13 vaccine for treatment of asthma

哮喘是仅次于癌症的世界第二大致死、致残疾病,造成的经济负担超过结核病和艾滋病的总和。严重的哮喘目前尚不能治愈,迫切需要新的有效的疾病干预手段。临床研究显示,白细胞介素-13(interfeukin-13,IL-13)与哮喘密切相关,动物模型研究也表明,IL-13在哮喘病理机制中处于核心位置。目前,IL-13单克隆抗体治疗哮喘在国外已处于Ⅱ期临床试验,以疫苗形式诱导持续的IL-13中和抗体,对哮喘这样的慢性疾病而言较之单抗更具应用潜能。本文对抗IL-13疫苗治疗哮喘的研究进展作一综述。

Asthma is a serious disease worldwide, of which the disability and death rates are only seconded to cancer. The financial burden of asthma is heavier than the sum of those of tuberculosis and AIDS. Severe asthma can not be cured by current therapies and treatments, resulting in an urgent need for novel efficient intervention. Clinical researches as well as animal model studies indicate that interleukin-13 （IL-13） plays a key role in asthma pathogenesis. At present, the treatment of asthma with IL-13 monoclonal antibodies （McAbs） has been studied in phase Ⅱ clinical trial. However, as compared with McAbs, the vaccines eliciting persistent neutralizing antibody against IL-13 is more applicable for chronic diseases such as asthma. This paper reviews the progress in research on anti-IL-13 vaccine for treatment of asthma.